［1］ LENDER JW,DUH QY,EISENHOFER G,et al.Pheochromocytoma and paraganglioma:an endocrine society clinical practice guideline［J］.J Clin Endocrinol Metab,2014,99(6):1915-1942.
［2］ NEUMANN HPH,YOUNG WF,ENG C.Pheochromocytoma and paraganglioma［J］.N Engl J Med,2019,381(6):552-565.
［3］ LENDERS JWM,KERSTENS MN,AMAR L,et al.Genetics,diagnosis,management and future directions of research of phaeochromocytoma and paraganglioma:a position statement and consensus of the working group on endocrine hypertension of the european society of hypertension［J］.J Hypertens,2020,38(8):1443-1456.
［4］ QUARTERMAINE G,LAMBERT K,REES K,et al.Hormone-secreting adrenal tumours cause severe hypertension and high rates of poor pregnancy outcome;a UK obstetric surveillance system study with case control comparisons［J］.BJOG,2018,125(6):719-727.
［5］ AYGUN N,ULUDAG M.Pheochromocytoma and paraganglioma:from clinical findings to diagnosis［J］.Sisli Etfal Hastan Tip Bul,2020,54(3):271-280.
［6］ VAN DER WEERD K,VAN NOORD C,LOEVE M,et al.Endocrinology in pregnancy:pheochromocytoma in pregnancy:case series and review of literature［J］.Eur J Endocrinol,2017,177(2):R49-R58.
［7］ DONATINI G,KRAIMPS JL,CAILLARD C,et al.Pheochromocytoma diagnosed during pregnancy:lessons learned from a series of ten patients［J］.Surg Endosc,2018,32(9):3890-3900.
［8］ SALAZAR-VEGA JL,LEVIN G,SANSO G,et al.Pheochromocytoma associated with pregnancy:unexpected favourable outcome in patients diagnosed after delivery［J］.J Hypertens,2014,32(7):1458-1463,discussion 1463.
［9］ DONG D,LI H.Diagnosis and treatment of pheochromocytoma during pregnancy［J］.J Matern Fetal Neonatal Med,2014,27(18):1930-1934.
［10］ PHOON JW,KANALINGAM D,CHUA HL.Adrenal tumours in pregnancy:diagnostic challenge and management dilemma［J］.Singapore Med J,2013,54(7):e141-145.
［11］ 徐维锋,李汉忠,严维刚,等.妊娠合并嗜铬细胞瘤的诊断与处理［J］.中华泌尿外科杂志,2011,32(4):254-257.
XU WF,LI HZ,YAN WG,et al.Diagnosis and management of pheochromocytoma in pregnancy［J］.Chin J Urol,2011,32(4):254-257.
［12］ BANCOS I,ATKINSON E,ENG C,et al.Maternal and fetal outcomes in phaeochromocytoma and pregnancy:a multicentre retrospective cohort study and systematic review of literature［J］.Lancet Diabetes Endocrinol,2021,9(1):13-21.
［13］ CLIFTON-BLIGH RJ.The diagnosis and management of pheochromocytoma and paraganglioma during pregnancy［J］.Rev Endocr Metab Disord,2023,24(1):49-56.
［14］ 中华医学会内分泌学分会.嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)［J］.中华内分泌代谢杂志,2020,36(9):737-750.
ENDOCRINOLOGY CSO.Expert consensus on the diagnosis and treatment of pheochromocytoma and paraganglioma (2020)［J］.Chin J Endocrinol Metab,2020,36(9):737-750.
［15］ PATEL D,PHAY JE,YEN TWF,et al.Update on pheochromocytoma and paraganglioma from the SSO endocrine/head and neck disease-site work group.part 1 of 2:advances in pathogenesis and diagnosis of pheochromocytoma and paraganglioma［J］.Ann Surg Oncol,2020,27(5):1329-1337.
［16］ FALHAMMAR H,KJELLMAN M,CALISSENDORFF J.Initial clinical presentation and spectrum of pheochromocytoma:a study of 94 cases from a single center［J］.Endocr Connect,2018,7(1):186-192.
［17］ EBBEHOJ A,STOCHHOLM K,JACOBSEN SF,et al.Incidence and clinical presentation of pheochromocytoma and sympathetic paraganglioma:a population-based study［J］.J Clin Endocrinol Metab,2021,106(5):e2251-e2261.
［18］ GRUBER LM,YOUNG WF,BANCOS I.Pheochromocytoma and paraganglioma in pregnancy:a new era［J］.Curr Cardiol Rep,2021,23(6):60.
［19］ GRUBER LM,HARTMAN RP,THOMPSON GB,et al.Pheochromocytoma characteristics and behavior differ depending on method of discovery［J］.J Clin Endocrinol Metab,2019,104(5):1386-1393.
［20］ VAN BERKEL A,LENDERS JW,TIMMERS HJ.Diagnosis of endocrine disease:biochemical diagnosis of phaeochromocytoma and paraganglioma［J］.Eur J Endocrinol,2014,170(3):R109-119.
［21］ CASTRO-VEGA LJ,LETOUZE E,BURNICHON N,et al.Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas［J］.Nat Commun,2015,6:6044.
［22］ JOCHMANOVA I,PACAK K.Genomic landscape of pheochromocytoma and paraganglioma［J］.Trends Cancer,2018,4(1):6-9.
［23］ GARCIA-CARBONERO R,MATUTE TERESA F,MERCADER-CIDONCHA E,et al.Multidisciplinary practice guidelines for the diagnosis,genetic counseling and treatment of pheochromocytomas and paragangliomas［J］.Clin Transl Oncol,2021,23(10):1995-2019.
［24］ PLOUIN PF,AMAR L,DEKKERS OM,et al.European society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma［J］.Eur J Endocrinol,2016,174(5):G1-G10.
［25］ AMAR L,FASSNACHT M,GIMENEZ-ROQUEPLO AP,et al.Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma［J］.Horm Metab Res,2012,44(5):385-389.
［26］ FAVIER J,AMAR L,GIMENEZ-ROQUEPLO AP.Paraganglioma and phaeochromocytoma:from genetics to personalized medicine［J］.Nat Rev Endocrinol,2015,11(2):101-111.
［27］ NICOLAS M,DAHIA P.Predictors of outcome in phaeochromocytomas and paragangliomas［J］.F1000Res,2017,6:2160.
［28］ KORAKITI AM,MOUTAFI M,ZOGRAFOS E,et al.The genomic profile of pregnancy-associated breast cancer:a systematic review［J］.Front Oncol,2020,10:1773.
［29］ 中华医学会外科学分会乳腺外科学组.妊娠相关性乳腺癌临床诊治专家共识(2020版)［J］.中华临床医师杂志（电子版）,2020,14(5):321-325.
BREAST SURGERY CSO.Expert consensus on clinical treatment of pregnancy-associated breast cancer (2020 Edition) ［J］.Chin J Clinicians(Electronic Edition),2020,14(5):321-325.
［30］ 石玉香,李莉,谢永辉,等.妊娠相关性乳腺癌临床病理特点及预后［J］.实用医学杂志,2021,37(5):632-636.
SHI YX,LI L,XIE YH,et al.Pathological features and prognosis of pregnancy-associated breast cancer［J］.The Journal of Practical Medicine,2021,37(5):632-636.
［31］ LOPEZ AG,DUPARC C,RENOUF S,et al.Expression of LHCGR in pheochromocytomas unveils an endocrine mechanism connecting pregnancy and epinephrine overproduction［J］.Hypertension,2022,79(5):1006-1016.